FFC#8/2014

Design and synthesis of improved analogs of trimethylangelicin (TMA) for personalized treatment of cystic fibrosis

AREA 1 Therapies to correct the underlying defect

FFC#8/2014

Design and synthesis of improved analogs of trimethylangelicin (TMA) for personalized treatment of cystic fibrosis
€ 0 still needed
0%
€ 45.000 goal

pRINCIPAL INVESTIGATOR

Roberto Gambari (Dip. di Scienze della Vita e Biotecnologie, Sez. di Biochimica e Biologia Molecolare, Università di Ferrara)

Partner

Adriana Chilin (Dip. di Farmaceutica e Scienze Farmacologiche, Università di Padova)

Researchers

10

Category

AREA 1 Therapies to correct the underlying defect

Duration

1 year

Goal

€ 45.000

Funds raised

€ 45.000

Objectives

The major objective of the project is to test TMA analogs with the aim offinding new antinflammatory agents and/or CFTR function modulators with equal or higher activity in respect to the parent TMA, and with absent DNA photobinding properties. In addition, the newly synthesized compounds will allow to derive structure-activity relationships on both the biological activities on inflammation and CFTR modulation. The goals of the project can be outlined in 5 sections: 1) design and synthesis of new TMA analogs; 2) test of photoreactivity; 3) test of the anti-inflammatory activity, based on inhibition of NFkB/ DNA interaction and expression of pro-inflammatory genes in CF bronchial cell lines and 4) test of the effects as CFTR function modulation; 5) derivation of structure-activity relationships aimed at rationalizing the structural determinants required to obtain selective anti-inflammatory properties, selective CFTR modulatory properties and dual antiinflammatory/ CFTR modulatory activity.

WHO ADOPTED THE PROJECT

Delegazione FFC di Bologna

€ 30.000

Delegazione FFC di Ferrara con il Gruppo di sostegno FFC di Comacchio

€ 15.000

Delegazione FFC di Manciano Grosseto

€ 15.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches